NASDAQ:XCUR

Exicure Stock Insider Trading

Healthcare > Biotechnology

Buy XCUR

*Your capital is at risk

$3.16

+0.0500 (+1.61%)

At Close: Jun 03, 2026

Exicure Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -28.54. In total, the insiders bought 13.39M and sold 26.65M XCUR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-28.54
● Buy	13.39M shares
● Sell	26.65M shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Jan 16, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -28.54. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 16, 2026 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	8 Value: $33
Jan 21, 2026 Sell	Common Stock S-Sale	Exicure Hitron Inc. 10 Percent Owner	10% Owner	258 367 Value: $1.16M
Jan 16, 2026 Sell	Common S-Sale	Exicure Hitron Inc. 10 Percent Owner	10% Owner	734 747 Value: $3.31M
Jan 07, 2026 Sell	Common S-Sale	Exicure Hitron Inc. 10 Percent Owner	10% Owner	741 272 Value: $3.34M
Dec 08, 2025 Sell	Common Stock S-Sale	Sangsangin Investment & Securities Co., Ltd. 10 Percent Owner	10% Owner	433 332 Value: $3.77M
Nov 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	7 Value: $26
Sep 08, 2025 Buy	Common Stock J-Other	Hwang Aejin	Director	0 Value: $0
Sep 08, 2025 Buy	Common Stock J-Other	Yeo Sangjin	Director	0 Value: $0
Sep 08, 2025 Buy	Common Stock J-Other	Yeo Sangjin	Director	0 Value: $0
Sep 08, 2025 Buy	Common Stock J-Other	Hwang Aejin	Director	0 Value: $0
Aug 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	9 Value: $60
Aug 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	9 Value: $60
May 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	8 Value: $80
May 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	8 Value: $80
Feb 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	9 Value: $90
Feb 16, 2025 Sell	Common Stock F-InKind	Miller Josh Chief Accounting Officer	Officer	9 Value: $90
Dec 26, 2024 Buy	Common Stock P-Purchase	Hitron Systems Inc. 10 Percent Owner	10% Owner	2 900 000 Value: $8.70M
Dec 26, 2024 Buy	Common Stock P-Purchase	Hitron Systems Inc. 10 Percent Owner	10% Owner	2 900 000 Value: $8.70M
Dec 19, 2024 Buy	Common Stock J-Other	Kang Min Woo	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock J-Other	Song Sang Wook	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock J-Other	Choi Chang Keun	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock J-Other	John Ho Jung	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock J-Other	John Ho Jung	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock J-Other	Choi Chang Keun	Director	0 Value: $0
Dec 19, 2024 Buy	Common Stock J-Other	Song Sang Wook	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EXICURE, INC.

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S...

Read Full Profile Here